Fig 1.
Blood sampling from lobectomy specimen.
When a lobectomy specimen of fresh lung tissue was submitted to the Department of Pathology to evaluate bronchial resection margin during surgery, peripheral blood was obtained from a pulmonary vessel.
Table 1.
Baseline characteristics of non-small cell carcinoma (n = 36).
Table 2.
Detailed results of EGFR and KRAS mutations in matched plasma and tissue samples.
Table 3.
Comparison of EGFR mutation status between matched tissue and plasma samples.
Table 4.
Comparison of KRAS mutation status between matched tissue and plasma samples.
Fig 2.
Box and whisker plot of pathological tumor size in non-shedding and shedding tumors.
Fig 3.
Box and whisker plot of tumor volume measured from chest CT in non-shedding and shedding tumors.
Fig 4.
Box and whisker plot of mitotic count per 10 high power fields in non-shedding and shedding tumors.
Fig 5.
Representative cases with ctDNA shedding in plasma.
A-B, A solid predominant adenocarcinoma with EGFR L858R mutation in both tissue and plasma (case no. 35). The tumor showed vascular invasion (A, ×40), necrosis (B; left side of the picture, ×200), cytological atypia, and frequent mitosis (B, arrow heads). C-D, A pneumonic-type adenocarcinoma with KRAS G12V mutation in both tissue and plasma (case no. 13). Large tumor in the right lower lobe on chest CT image is delineated by arrow heads (C). The tumor showed adenocarcinoma with mixed papillary and lepidic pattern (D, ×40).
Table 5.
Clinicopathological parameters according to the mutant ctDNA in EGFR or KRAS-mutant lung adenocarcinoma (n = 21).
Table 6.
Subgroup analysis of clinicopathological parameters according to the mutant ctDNA in EGFR-mutant lung adenocarcinoma (n = 15).